PDS Biotechnology Corp — Form SCHEDULE 13D
Filed September 21, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 42/100
What the filing says
NANT Capital, LLC filed a Schedule 13D on September 21, 2026, indicating acquisition of beneficial ownership in PDS Biotechnology Corp (market cap ~$60.1M). The filing does not disclose the specific percentage stake, share count, or dollar amount of the acquisition in the text provided—only that NANT Capital has filed the required disclosure document. Additional details are referenced in attached exhibits but not summarized in the main filing text.
Why this rating
Schedule 13D alone is routine disclosure; significance depends on undisclosed stake size. Material if >5-10% of $60M company, but specifics absent here.
See more from September 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.